{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:19:02Z","timestamp":1773296342031,"version":"3.50.1"},"reference-count":25,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Asthma"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1080\/02770903.2020.1713147","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T07:56:52Z","timestamp":1579593412000},"page":"633-644","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Long-term safety and efficacy studies of epinephrine HFA metered-dose inhaler (Primatene\n            <sup>\u00ae<\/sup>\n            Mist): a two-stage randomized controlled trial"],"prefix":"10.1080","volume":"58","author":[{"given":"Edward M.","family":"Kerwin","sequence":"first","affiliation":[{"name":"Clinical Research Institute of Southern Oregon","place":["Medford, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California at Los Angeles","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip E.","family":"Korenblat","sequence":"additional","affiliation":[{"name":"The Clinical Research Center, LLC","place":["St Louis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon S.","family":"Greos","sequence":"additional","affiliation":[{"name":"Colorado Allergy and Asthma Centers, PC","place":["Centennial, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Pearlman","sequence":"additional","affiliation":[{"name":"Colorado Allergy and Asthma Centers, PC","place":["Denver, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Bensch","sequence":"additional","affiliation":[{"name":"Allergy, Immunology, and Asthma Medical Group Inc.","place":["Stockton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. David","family":"Miller","sequence":"additional","affiliation":[{"name":"Northeast Medical Research Associates, Inc.","place":["North Dartmouth, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Marrs","sequence":"additional","affiliation":[{"name":"Amphastar Pharmaceuticals, Inc.","place":["Rancho Cucamonga, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Z.","family":"Luo","sequence":"additional","affiliation":[{"name":"Amphastar Pharmaceuticals, Inc.","place":["Rancho Cucamonga, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack Y.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Amphastar Pharmaceuticals, Inc.","place":["Rancho Cucamonga, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"e_1_3_1_2_1","unstructured":"Federal Register Volume 73 no 224: 21 CFR Part 2: use of ozone-depleting substances; removal of essential-use designation (epinephrine). Final rule. 2008."},{"key":"e_1_3_1_3_1","unstructured":"Gao J Luo J Zhou R Luo MZ Zhang JY . Stable epinephrine suspension formulation with high inhalation delivery efficiency. US Patent 8 367 734 B1. Feb. 5 2013. Available from: https:\/\/patentimages.storage.googleapis.com\/67\/65\/d4\/461c6f9a24c31a\/US8367734.pdf [last accessed 18 December 2019]."},{"key":"e_1_3_1_4_1","unstructured":"Gottlieb S Woodcock J . FDA statement on approval of OTC Primatene Mist to treat mild asthma. 2018 Nov. 8. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-approval-otc-primatene-mist-treat-mild-asthma [last accessed 15 September 2018]."},{"key":"e_1_3_1_5_1","unstructured":"National Asthma Education and Prevention Program Third Expert Panel on the Diagnosis and Management of Asthma . Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart Lung and Blood Institute (US); 2007 Aug. Report No.: 07-4051. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK7232\/ [last accessed 9 September 2015]."},{"key":"e_1_3_1_6_1","unstructured":"Global Initiative for Asthma . Global Strategy for Asthma Management and Prevention 2019. Available from: www.ginasthma.org [last accessed 2 August 2019]."},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S121733"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.5847\/wjem.j.issn.1920-8642.2013.04.001"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61014-9"},{"key":"e_1_3_1_10_1","unstructured":"International Conference on Harmonization E9: Statistical Principles for Clinical Trials . 1998. Available from: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073137.pdf [last accessed 5 May 2015]."},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.02.001"},{"key":"e_1_3_1_12_1","first-page":"A1278","article-title":"A cumulative dose (1440\u2009\u03bcg) study to evaluate the efficacy, PK, extrapulmonary PD, and safety of albuterol sulfate MDI in co-suspension delivery technology (AS MDI; PT007) in patients with asthma","volume":"199","author":"Maes A","year":"2019","unstructured":"Maes A , Cappelletti C , Rossman K , Gillen M , LaForce CF , Reisner C . A cumulative dose (1440\u2009\u03bcg) study to evaluate the efficacy, PK, extrapulmonary PD, and safety of albuterol sulfate MDI in co-suspension delivery technology (AS MDI; PT007) in patients with asthma. Am J Respir Crit Care Med. 2019;199:A1278.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2017.38.4015"},{"key":"e_1_3_1_14_1","volume-title":"Respiratory care pharmacology","author":"Gardenhire DS","year":"2012","unstructured":"Gardenhire DS . Respiratory care pharmacology. 8th ed. St. Louis, MO: Elsevier-Mosby; 2012.","edition":"8"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201209-1739PP"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:31:2:279"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14b08.x"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00067503"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.130045"},{"key":"e_1_3_1_20_1","first-page":"A3810","article-title":"No tachyphylaxis following chronic use of albuterol multidose dry powder inhaler in children with asthma over 3 weeks","volume":"193","author":"LaForce C","year":"2016","unstructured":"LaForce C , Taveras H , Iverson H . No tachyphylaxis following chronic use of albuterol multidose dry powder inhaler in children with asthma over 3 weeks. Am J Respir Crit Care Med. 2016;193:A3810. [Online Abstracts issue].","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.243"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70250-7"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2011.12.004"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.12974\/2311-8687.2013.01.01.2"},{"key":"e_1_3_1_25_1","unstructured":"Proventil\u00ae HFA [package insert]. Whitehouse Station NJ: Merck&CO. Inc.; 2012."},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.7705\/biomedica.v38i3.3813"}],"container-title":["Journal of Asthma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02770903.2020.1713147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:03:51Z","timestamp":1750914231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02770903.2020.1713147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,4]]}},"alternative-id":["10.1080\/02770903.2020.1713147"],"URL":"https:\/\/doi.org\/10.1080\/02770903.2020.1713147","relation":{},"ISSN":["0277-0903","1532-4303"],"issn-type":[{"value":"0277-0903","type":"print"},{"value":"1532-4303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}